Tower Research Capital LLC TRC Sells 28,766 Shares of Augmedix, Inc. (NASDAQ:AUGX)

Tower Research Capital LLC TRC decreased its position in Augmedix, Inc. (NASDAQ:AUGX) by 78.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,062 shares of the company’s stock after selling 28,766 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Augmedix were worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of AUGX. Russell Investments Group Ltd. lifted its position in Augmedix by 292.0% in the 4th quarter. Russell Investments Group Ltd. now owns 891,077 shares of the company’s stock worth $5,213,000 after buying an additional 663,778 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in Augmedix in the 3rd quarter worth approximately $2,237,000. Calamos Advisors LLC purchased a new position in Augmedix in the 4th quarter worth approximately $886,000. Taylor Frigon Capital Management LLC purchased a new position in Augmedix in the 3rd quarter worth approximately $438,000. Finally, Perkins Capital Management Inc. increased its stake in Augmedix by 5.3% in the 4th quarter. Perkins Capital Management Inc. now owns 1,464,568 shares of the company’s stock worth $8,568,000 after purchasing an additional 73,475 shares during the period. Institutional investors own 87.11% of the company’s stock.

Augmedix Trading Down 4.2 %

Shares of AUGX traded down $0.12 during mid-day trading on Tuesday, hitting $2.71. 223,834 shares of the company’s stock traded hands, compared to its average volume of 362,462. The company has a quick ratio of 2.41, a current ratio of 2.41 and a debt-to-equity ratio of 0.66. Augmedix, Inc. has a 1 year low of $2.61 and a 1 year high of $6.25. The firm has a market capitalization of $132.09 million, a P/E ratio of -6.02 and a beta of -0.16. The business’s 50-day moving average price is $3.77 and its 200-day moving average price is $4.64.

Augmedix (NASDAQ:AUGX) last posted its earnings results on Monday, March 18th. The company reported ($0.09) earnings per share (EPS) for the quarter. Augmedix had a negative net margin of 42.74% and a negative return on equity of 308.50%. The business had revenue of $12.68 million for the quarter, compared to analysts’ expectations of $12.30 million. As a group, sell-side analysts forecast that Augmedix, Inc. will post -0.51 EPS for the current fiscal year.

Insider Activity at Augmedix

In related news, insider Ian Shakil sold 58,978 shares of Augmedix stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $3.91, for a total transaction of $230,603.98. Following the sale, the insider now directly owns 180,034 shares in the company, valued at $703,932.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 251,323 shares of company stock worth $1,005,527 over the last ninety days. 10.97% of the stock is owned by corporate insiders.

Analyst Ratings Changes

AUGX has been the topic of a number of analyst reports. Maxim Group decreased their price target on Augmedix from $6.50 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, March 19th. Evercore ISI raised Augmedix from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $4.50 to $5.00 in a research note on Tuesday, April 9th. Finally, B. Riley assumed coverage on Augmedix in a research note on Wednesday, April 3rd. They issued a “buy” rating and a $5.50 price target on the stock.

About Augmedix

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.